Insulin resistance, low-grade inflammation and type 1 diabetes mellitus

Acta Diabetologica

Volumn 49, Issue 1, 2012, Pages 33-39

  Llaurado G ^a   Gallart, L ^b   Tirado, R ^a   Megia, A ^b   Simon I ^b   Caixas A ^a   Gimenez Palop O ^a   Berlanga, E ^a   Vendrell, J ^b   Gonzalez Clemente J M ^a  

^a PARC TAULÍ HOSPITAL UNIVERSITARI   (Spain)

^b HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

Author keywords

Insulin resistance; Low grade inflammation; Type 1 diabetes

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CAPTOPRIL; ENALAPRIL; HEMOGLOBIN A1C; INTERLEUKIN 6; LEPTIN; LEVOTHYROXINE; LIPID; QUINAPRIL; SOLUBLE TUMOR NECROSIS FACTOR ALPHA RECEPTOR 1; SOLUBLE TUMOR NECROSIS FACTOR ALPHA RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG; INSULIN;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETIC MICROANGIOPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ESTIMATION OF THE GLUCOSE DISPOSAL RATE; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SMOKING; SYSTOLIC BLOOD PRESSURE; WAIST HIP RATIO; ADOLESCENT; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; COHORT ANALYSIS; GLUCOSE BLOOD LEVEL; METABOLISM; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADOLESCENT; ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; C-REACTIVE PROTEIN; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; MALE; YOUNG ADULT;

EID: 84861699012     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-011-0257-1     Document Type: Article

References (40)

1. Pambianco G, Costacou T, Orchard TJ (2007) The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study Experience. Diabetes Care 30(5):1248-1254 (Pubitemid 46684655)
2. Thorn LM, Forsblom C, Fagerudd J, Thomas MC, Pettersson- Fernholm K, Saraheimo M, Waden J, Ronnback M, Rosengard- Barlund M, Bjorkesten CG, Taskinen MR, Groop PH (2005) Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 28(8):2019-2024 (Pubitemid 41060978)
3. Orchard TJ, Chang YF, Ferrell RE, Petro N, Ellis DE (2002) Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study. Kidney Int 62(3):963-970 (Pubitemid 35316726)
4. Orchard TJ, Olson JC, Erbey JR, Williams K, Forrest KY, Smithline Kinder L, Ellis D, Becker DJ (2003) Insulin resistancerelated factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 26(5):1374-1379 (Pubitemid 36929165)
5. Kilpatrick ES, Rigby AS, Atkin SL (2007) Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: "double diabetes" in the diabetes control and complications trial. Diabetes Care 30(3):707-712 (Pubitemid 46354357)
6. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD (2005) Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes - the EURODIAB Prospective Complications Study. Diabetologia 48(2):370-378 (Pubitemid 40543311)
7. Saraheimo M, Teppo AM, Forsblom C, Fagerudd J, Groop PH (2003) Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetologia 46(10): 1402-1407 (Pubitemid 37297211)
8. Gonzalez-Clemente JM, Mauricio D, Richart C, Broch M, Caixas A, Megia A, Gimenez-Palop O, Simon I, Martinez-Riquelme A, Gimenez-Perez G, Vendrell J (2005) Diabetic neuropathy is associated with activation of the TNF-alpha system in subjects with type 1 diabetes mellitus. Clin Endocrinol 63(5):525-529 (Pubitemid 41626747)
9. Colhoun HM, Schalkwijk C, Rubens MB, Stehouwer CD (2002) C-reactive protein in type 1 diabetes and its relationship to coronary artery calcification. Diabetes Care 25(10):1813-1817 (Pubitemid 41071092)
10. Gonzalez-Clemente JM, Vilardell C, Broch M, Megia A, Caixas A, Gimenez-Palop O, Richart C, Simon I, Martinez-Riquelme A, Arroyo J, Mauricio D, Vendrell J (2007) Lower heart rate variability is associated with higher plasma concentrations of IL-6 in type 1 diabetes. Eur J Endocrinol 157(1):31-38 (Pubitemid 47162563)
11. Laaksonen DE, Niskanen L, Nyyssonen K, Punnonen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT (2004) C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 47(8):1403-1410
12. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM (2000) Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102(1):42-47 (Pubitemid 30430551)
13. Tan KC, Chow WS, Tam S, Bucala R, Betteridge J (2004) Association between acute-phase reactants and advanced glycation end products in type 2 diabetes. Diabetes Care 27(1):223-228 (Pubitemid 38196736)
14. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH (2002) Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 51(4):1157-1165 (Pubitemid 34438363)
15. Fernandez-Real JM, Ricart W (2003) Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 24(3):278-301 (Pubitemid 36724371)
16. Su SC, Pei D, Hsieh CH, Hsiao FC, Wu CZ, Hung YJ (2010) Circulating pro-inflammatory cytokines and adiponectin in young men with type 2 diabetes. Acta diabetologica Jan 8 (Epub ahead of print)
17. Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, Youngren JF, Havel PJ, Pratley RE, Bogardus C, Tataranni PA (2002) Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 51(6):1884-1888 (Pubitemid 34564302)
18. King GA, Deemer SE, Thompson DL (2010) Adiponectin is associated with risk of the metabolic syndrome and insulin resistance in women. Acta diabetologica May 8 (Epub ahead of print)
19. Ruan W, Lai M (2010) Insulin-like growth factor binding protein: a possible marker for the metabolic syndrome? Acta Diabetol 47(1):5-14
20. Goday A, Castell C, Tresserras R, Canela J, Taberner JL, Lloveras G (1992) Incidence of type 1 (insulin-dependent) diabetes mellitus in Catalonia, Spain. The Catalan epidemiology diabetes study group. Diabetologia 35(3):267-271
21. Brun JF, Ghanassia E, Fedou C, Bordenave S, Raynaud de Mauverger E, Mercier J (2010) Assessment of insulin sensitivity (S(I)) and glucose effectiveness (S (G)) from a standardized hyperglucidic breakfast test in type 2 diabetics exhibiting various levels of insulin resistance. Acta diabetologica Oct 28 (Epub ahead of print)
22. Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ (2000) Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 49(4):626-632 (Pubitemid 30183752)
23. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6):499-502
24. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA (1994) A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 17(11):1281-1289 (Pubitemid 24324972)
25. Saltevo J, Vanhala M, Kautiainen H, Kumpusalo E, Laakso M (2008) Gender differences in C-reactive protein, interleukin-1 receptor antagonist and adiponectin levels in the metabolic syndrome: a population-based study. Diabet Med 25(6):747-750 (Pubitemid 351782826)
26. Saraheimo M, Forsblom C, Fagerudd J, Teppo AM, Pettersson- Fernholm K, Frystyk J, Flyvbjerg A, Groop PH (2005) Serum adiponectin is increased in type 1 diabetic patients with nephropathy. Diabetes Care 28(6):1410-1414 (Pubitemid 40756705)
27. Jenkins AJ, Rothen M, Klein RL, Moller K, Eldridge L, Zheng D, Durazo-Arvizu R, McGee D, Lackland D, Thorpe SR, Garvey WT, Lyons TJ (2008) Cross-sectional associations of C-reactive protein with vascular risk factors and vascular complications in the DCCT/EDIC cohort. J Diabetes Complicat 22(3):153-163 (Pubitemid 351539060)
28. Mackness B, Hine D, McElduff P, Mackness M (2006) High C-reactive protein and low paraoxonase1 in diabetes as risk factors for coronary heart disease. Atherosclerosis 186(2): 396-401
29. Hayaishi-Okano R, Yamasaki Y, Katakami N, Ohtoshi K, Gorogawa S, Kuroda A, Matsuhisa M, Kosugi K, Nishikawa N, Kajimoto Y, Hori M (2002) Elevated C-reactive protein associates with early-stage carotid atherosclerosis in young subjects with type 1 diabetes. Diabetes Care 25(8):1432-1438 (Pubitemid 41071157)
30. Schram MT, Chaturvedi N, Schalkwijk C, Giorgino F, Ebeling P, Fuller JH, Stehouwer CD (2003) Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care 26(7):2165-2173 (Pubitemid 41184269)
31. Kilpatrick ES, Keevil BG, Jagger C, Spooner RJ, Small M (2000) Determinants of raised C-reactive protein concentration in type 1 diabetes. QJM 93(4):231-236 (Pubitemid 30198960)
32. Schalkwijk CG, Poland DC, van Dijk W, Kok A, Emeis JJ, Drager AM, Doni A, van Hinsbergh VW, Stehouwer CD (1999) Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 42(3):351-357 (Pubitemid 29111443)
33. Willerson JT, Ridker PM (2004) Inflammation as a cardiovascular risk factor. Circulation 109(21 Suppl 1):II2-10
34. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM (1995) Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95(5):2409-2415
35. Picardi A, Valorani MG, Vespasiani Gentilucci U, Manfrini S, Ciofini O, Cappa M, Guglielmi C, Pozzilli P (2007) Raised C-reactive protein levels in patients with recent onset type 1 diabetes. Diabetes Metab Res Rev 23(3):211-214 (Pubitemid 46437846)
36. Blum CA, Muller B, Huber P, Kraenzlin M, Schindler C, De Geyter C, Keller U, Puder JJ (2005) Low-grade inflammation and estimates of insulin resistance during the menstrual cycle in lean and overweight women. J Clin Endocrinol Metab 90(6):3230-3235 (Pubitemid 41014280)
37. Carlson CS, Aldred SF, Lee PK, Tracy RP, Schwartz SM, Rieder M, Liu K, Williams OD, Iribarren C, Lewis EC, Fornage M, Boerwinkle E, Gross M, Jaquish C, Nickerson DA, Myers RM, Siscovick DS, Reiner AP (2005) Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet 77(1):64-77 (Pubitemid 40848037)
38. Eklund C, Kivimaki M, Islam MS, Juonala M, Kahonen M, Marniemi J, Lehtimaki T, Viikari J, Raitakari OT, Hurme M (2008) C-reactive protein genetics is associated with carotid artery compliance in men in the cardiovascular risk in young finns study. Atherosclerosis 196(2):841-848
39. Lange LA, Carlson CS, Hindorff LA, Lange EM, Walston J, Durda JP, Cushman M, Bis JC, Zeng D, Lin D, Kuller LH, Nickerson DA, Psaty BM, Tracy RP, Reiner AP (2006) Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events. JAMA 296(22):2703-2711 (Pubitemid 44917547)
40. Szalai AJ, Wu J, Lange EM, McCrory MA, Langefeld CD, Williams A, Zakharkin SO, George V, Allison DB, Cooper GS, Xie F, Fan Z, Edberg JC, Kimberly RP (2005) Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level. J Mol Med (Berlin, Germany) 83(6):440-447 (Pubitemid 40922166)